| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Contineum Therapeutics, Inc. | CMO & Head of Development | Class A Common Stock | 0 | $0 | $12.06 | 29 Dec 2025 | Direct |
| Contineum Therapeutics, Inc. | CMO & Head of Development | Stock Option (right to buy) | 256,389 | 29 Dec 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| CTNM | Contineum Therapeutics, Inc. | 29 Dec 2025 | 3 | -$27,309 | 4 | CMO & Head of Development | 30 Dec 2025, 16:12 |
| CTNM | Contineum Therapeutics, Inc. | 28 Apr 2025 | 2 | $0 | 4 | CMO & Head of Development | 28 Apr 2025, 16:21 |
| CTNM | Contineum Therapeutics, Inc. | 28 Apr 2025 | 0 | $0 | 3 | CMO & Head of Development | 28 Apr 2025, 16:16 |